title: Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
abstract: The QFlu prototype bioluminescence-based neuraminidase (NA) inhibition (NI) assay kit was designed to detect NA inhibitor (NAI)-resistant influenza viruses at point of care. Here, we evaluated its suitability for drug susceptibility assessment at a surveillance laboratory. A comprehensive panel of reference viruses (n = 14) and a set of 90 seasonal influenza virus A and B isolates were included for testing with oseltamivir and/or zanamivir in the QFlu assay using the manufacturer-recommended protocol and a modified version attuned to surveillance requirements. The 50% inhibitory concentrations (IC50s) generated were compared with those of NI assays currently used for monitoring influenza drug susceptibility, the fluorescent (FL) and chemiluminescent (CL) assays. To provide proof of principle, clinical specimens (n = 235) confirmed by real-time reverse transcription (RT)-PCR to contain influenza virus A(H1N1)pdm09 and prescreened for the oseltamivir resistance marker H275Y using pyrosequencing were subsequently tested in the QFlu assay. All three NI assays were able to discriminate the reference NA variants and their matching wild-type viruses based on the difference in their IC50s. Unless the antigenic types were first identified, certain NA variants (e.g., H3N2 with E119V) could be detected among seasonal viruses using the FL assays only. Notably, the QFlu assay identified oseltamivir-resistant A(H1N1)pdm09 viruses carrying the H275Y marker directly in clinical specimens, which is not feasible with the other two phenotypic assays, which required prior virus culturing in cells. Furthermore, The QFlu assay allows detection of the influenza virus A and B isolates carrying established and potential NA inhibitor resistance markers and may become a useful tool for monitoring drug resistance in clinical specimens.
authors.affiliation: Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
authors.forename: Henju
authors.initials: H
authors.lastname: Marjuki
authors.forename: Vasiliy P
authors.initials: VP
authors.lastname: Mishin
authors.forename: Katrina
authors.initials: K
authors.lastname: Sleeman
authors.forename: Margaret
authors.initials: M
authors.lastname: Okomo-Adhiambo
authors.forename: Tiffany G
authors.initials: TG
authors.lastname: Sheu
authors.forename: Lizheng
authors.initials: L
authors.lastname: Guo
authors.forename: Xiyan
authors.initials: X
authors.lastname: Xu
authors.forename: Larisa V
authors.initials: LV
authors.lastname: Gubareva
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000187:drug effects*; D057075:Enzyme Assays; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000302:isolation & purification; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects / Q000302:isolation & purification; D009981:Influenza B virus / Q000187:drug effects / Q000302:isolation & purification; D007251:Influenza, Human / Q000821:virology; D007700:Kinetics; D008163:Luminescent Measurements; D008826:Microbial Sensitivity Tests; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053139:Oseltamivir / Q000494:pharmacology*; D011485:Protein Binding; D014764:Viral Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053243:Zanamivir / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D014764:Viral Proteins; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir
references.citation: Emerg Infect Dis. 2011 Nov;17(11):2043-6
references.pmid: 22099093
references.citation: Pediatr Infect Dis J. 2011 Apr;30(4):284-8
references.pmid: 21048522
references.citation: Clin Infect Dis. 2008 Aug 1;47(3):339-45
references.pmid: 18582202
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
references.pmid: 18625765
references.citation: Antiviral Res. 2009 Jul;83(1):90-3
references.pmid: 19501261
references.citation: JAMA. 2009 Mar 11;301(10):1034-41
references.pmid: 19255110
references.citation: PLoS One. 2010 Nov 30;5(11):e14158
references.pmid: 21152402
references.citation: PLoS One. 2011;6(8):e23627
references.pmid: 21858186
references.citation: Methods Mol Biol. 2012;865:95-113
references.pmid: 22528155
references.citation: Antimicrob Agents Chemother. 2006 May;50(5):1872-4
references.pmid: 16641465
references.citation: Expert Rev Anti Infect Ther. 2012 Feb;10(2):123-43
references.pmid: 22339187
references.citation: Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74
references.pmid: 23061103
references.citation: J Clin Microbiol. 2011 Jul;49(7):2614-9
references.pmid: 21593260
references.citation: J Infect Dis. 1998 Nov;178(5):1257-62
references.pmid: 9780244
references.citation: Antiviral Res. 2012 Mar;93(3):381-6
references.pmid: 22330888
references.citation: Antimicrob Agents Chemother. 2010 Sep;54(9):3671-7
references.pmid: 20585136
references.citation: Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402
references.pmid: 16801417
references.citation: Viruses. 2010 Oct;2(10):2269-89
references.pmid: 21994620
references.citation: Methods Mol Biol. 2012;865:115-25
references.pmid: 22528156
references.citation: Antiviral Res. 2010 Feb;85(2):381-8
references.pmid: 19917319
references.citation: Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82
references.pmid: 20368393
references.citation: JAMA. 2006 Feb 22;295(8):891-4
references.pmid: 16456087
references.citation: Carbohydr Res. 2012 Oct 1;359:92-6
references.pmid: 22925770
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1102-10
references.pmid: 20028826
references.citation: JAMA. 2007 Apr 4;297(13):1435-42
references.pmid: 17405969
references.citation: Antiviral Res. 2002 Jan;53(1):47-61
references.pmid: 11684315
references.citation: Emerg Infect Dis. 2009 Apr;15(4):552-60
references.pmid: 19331731
references.citation: J Infect Dis. 2003 Jul 1;188(1):57-61
references.pmid: 12825171
references.citation: Antimicrob Agents Chemother. 2010 May;54(5):1834-41
references.pmid: 20194700
references.citation: Arch Virol. 1976;52(1-2):7-18
references.pmid: 63277
references.citation: Rev Med Virol. 2000 Jan-Feb;10(1):45-55
references.pmid: 10654004
references.citation: Clin Infect Dis. 2006 Aug 15;43(4):439-44
references.pmid: 16838232
references.citation: J Infect. 2009 Sep;59(3):207-12
references.pmid: 19619898
references.citation: Clin Infect Dis. 2009 Dec 15;49(12):1828-35
references.pmid: 19911968
references.citation: Antiviral Res. 2011 Jul;91(1):20-2
references.pmid: 21549758
references.citation: J Infect Chemother. 2003 Sep;9(3):195-200
references.pmid: 14513385
references.citation: J Virol. 2010 Jul;84(13):6769-81
references.pmid: 20410266